These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 35860245)

  • 41. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
    Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
    Front Immunol; 2020; 11():1091. PubMed ID: 32574263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
    Lu W; Yan L; Tang X; Wang X; Du J; Zou Z; Li L; Ye J; Zhou L
    J Transl Med; 2024 Jun; 22(1):550. PubMed ID: 38851730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Roehrig S; Ait Hssain A; Shallik NAH; Elsaid IMA; Mustafa SF; Smain OAM; Molokhia AA; Lance MD
    Trials; 2020 Sep; 21(1):781. PubMed ID: 32917259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
    Bowdish ME; Barkauskas CE; Overbey JR; Gottlieb RL; Osman K; Duggal A; Marks ME; Hupf J; Fernandes E; Leshnower BG; Golob JL; Iribarne A; Rassias AJ; Moquete EG; O'Sullivan K; Chang HL; Williams JB; Parnia S; Patel NC; Desai ND; Vekstein AM; Hollister BA; Possemato T; Romero C; Hou PC; Burke E; Hayes J; Grossman F; Itescu S; Gillinov M; Pagani FD; O'Gara PT; Mack MJ; Smith PK; Bagiella E; Moskowitz AJ; Gelijns AC
    Am J Respir Crit Care Med; 2023 Feb; 207(3):261-270. PubMed ID: 36099435
    [No Abstract]   [Full Text] [Related]  

  • 45. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
    Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
    Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
    Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
    Trials; 2022 May; 23(1):401. PubMed ID: 35562778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study.
    Sánchez-Guijo F; García-Arranz M; López-Parra M; Monedero P; Mata-Martínez C; Santos A; Sagredo V; Álvarez-Avello JM; Guerrero JE; Pérez-Calvo C; Sánchez-Hernández MV; Del-Pozo JL; Andreu EJ; Fernández-Santos ME; Soria-Juan B; Hernández-Blasco LM; Andreu E; Sempere JM; Zapata AG; Moraleda JM; Soria B; Fernández-Avilés F; García-Olmo D; Prósper F
    EClinicalMedicine; 2020 Aug; 25():100454. PubMed ID: 32838232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.
    Ware LB; Soleymanlou N; McAuley DF; Estrada V; Diaz GA; Lacamera P; Kaste R; Choi W; Gupta A; Welte T
    Thorax; 2023 Aug; 78(8):816-824. PubMed ID: 37024277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients.
    Saeed MAM; Mohamed AH; Owaynat AH
    Egypt J Intern Med; 2022; 34(1):19. PubMed ID: 35194371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
    Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA
    J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fresh and Cryopreserved Human Umbilical-Cord-Derived Mesenchymal Stromal Cells Attenuate Injury and Enhance Resolution and Repair following Ventilation-Induced Lung Injury.
    Horie S; Gonzalez H; Brady J; Devaney J; Scully M; O'Toole D; Laffey JG
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
    Xu Z; Huang Y; Zhou J; Deng X; He W; Liu X; Li Y; Zhong N; Sang L
    Front Immunol; 2021; 12():738697. PubMed ID: 34659231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial.
    Richard JC; Yonis H; Bitker L; Roche S; Wallet F; Dupuis C; Serrier H; Argaud L; Thiery G; Delannoy B; Pommier C; Abraham P; Muller M; Aubrun F; Sigaud F; Rigault G; Joffredo E; Mezidi M; Terzi N; Rabilloud M
    Trials; 2021 Oct; 22(1):692. PubMed ID: 34635128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
    Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP
    Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome.
    Beloncle F; Studer A; Seegers V; Richard JC; Desprez C; Fage N; Merdji H; Pavlovsky B; Helms J; Cunat S; Mortaza S; Demiselle J; Brochard L; Mercat A; Meziani F
    Crit Care; 2021 Jul; 25(1):248. PubMed ID: 34266454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical characteristics of pediatric patients with acute respiratory distress syndrome due to COVID-19.
    Marroquín-Yáñez ML; Medeiros M; Chávez-López A; Carrillo-López HA; Soto-Bautista NP; Jarillo-Quijada AE; Gómez-Murillo SY; Láscari-Jiménez EC; Ruiz-Quiñones G; Barrera-Alonzo CJ; Contras-Santiago EM; Hernández-Hernández M
    Bol Med Hosp Infant Mex; 2022; 79(3):170-179. PubMed ID: 35882022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life.
    Sitbon A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Lebbah S; Ropers J; Salem JE; Straus C; Menasché P; Larghero J; Monsel A;
    Stem Cell Res Ther; 2024 Apr; 15(1):109. PubMed ID: 38637891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris.
    Schmidt M; Langouet E; Hajage D; James SA; Chommeloux J; Bréchot N; Barhoum P; Lefèvre L; Troger A; de Chambrun MP; Hékimian G; Luyt CE; Dres M; Constantin JM; Fartoukh M; Leprince P; Lebreton G; Combes A;
    Crit Care; 2021 Oct; 25(1):355. PubMed ID: 34627350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.